Remote blood pressure monitoring service standardizes BP collection
PHILADELPHIA – June 10, 2021 – ERT, the global leader in clinical endpoint data collection, today announced the expansion of its clinical trial endpoint data collection portfolio with at-home blood pressure (BP) monitoring solution. This completes a suite of blood pressure assessment services developed by ERT that allow for greater flexibility in collecting patients’ blood pressure in traditional, hybrid, and decentralized trial environments.
“High quality blood pressure data is critical evidence in many types of clinical trials, and our customers rely on us to provide the innovations that deliver it, whether the assessment is conducted in-clinic or remotely,” said Ellen Street, Product Line Executive of Cardiac Safety Solutions at ERT. “By offering blood pressure collection at home, we increase patient compliance and the frequency of data collection for better safety assessment.”
ERT’s specialized software secures BP data capture, ensuring higher quality data for confident decision making than other self-reported home blood pressure collection options. ERT’s easy-to-use monitor and tailored application with built-in workflow ensure the patient follows instructions for accurate data collection from their home, then sends real-time patient data for immediate investigator review.
“In the traditional setting of a physician’s office, blood pressure collection can be influenced by a ‘white coat effect’ in which a patient’s reaction to the visit causes a rise in blood pressure,” stated Street. “This is another one of the reasons we recommend home blood pressure monitoring in addition to in-clinic. It can actually yield more accurate data.”
ERT is the market leader in cardiac safety solutions, providing clinically validated solutions and the experience and expertise to support cardiac safety needs for all phases of clinical trials. As ERT merges with BioClinica, the joint company’s combined industry expertise and market leadership will drive its commitment to provide complete solutions to enable high quality, clinical-grade endpoint data collection in traditional, hybrid, and decentralized clinical trials.
For more information on ERT’s remote BP monitoring service, visit ert.com/cardiac-safety/.
ERT (eResearch Technology) is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.
Powered by the company’s EXPERT® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. In 2019, 75% of all FDA drug approvals came from ERT-supported studies. Pharma companies, biotechs, and CROs have relied on ERT solutions across 16,000 studies, spanning more than five million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly ─ and with confidence.
ERT Media Contact:
Director, Thought Leadership and Public Relations